MediciNova, Inc. (4875.T)
JPY 336.0
(0.9%)
JPY 336.0
(0.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -50.78 Million USD | -176.78% |
| 2022 | -18.34 Million USD | 74.27% |
| 2021 | -71.29 Million USD | -19.13% |
| 2020 | -59.85 Million USD | 0.0% |
| 2019 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -44.14 Million USD | 5.91% |
| 2024 Q1 | -46.92 Million USD | 7.61% |
| 2023 Q3 | -50.83 Million USD | 2.53% |
| 2023 Q2 | -52.15 Million USD | 4.53% |
| 2023 FY | -50.78 Million USD | -176.78% |
| 2023 Q1 | -54.62 Million USD | 0.0% |
| 2023 Q4 | -50.78 Million USD | 0.11% |
| 2022 Q4 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 106.837% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 95.522% |
| GNI Group Ltd. | -17.93 Billion JPY | 99.717% |
| Linical Co., Ltd. | -4.46 Billion JPY | 98.862% |
| Trans Genic Inc. | -221.16 Million JPY | 77.039% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 98.844% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 98.94% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 103.543% |
| AnGes, Inc. | -3.79 Billion JPY | 98.663% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 87.932% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 100.204% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 89.806% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 89.11% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 98.123% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 97.31% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 94.829% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 98.505% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 95.091% |
| Kidswell Bio Corporation | 343.58 Million JPY | 114.78% |
| PeptiDream Inc. | 3.29 Billion JPY | 101.543% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 94.779% |
| Ribomic Inc. | -2.09 Billion JPY | 97.581% |
| SanBio Company Limited | -3.78 Billion JPY | 98.66% |
| Healios K.K. | -2.19 Billion JPY | 97.681% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 94.625% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 98.065% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 96.416% |
| StemRIM | -8.41 Billion JPY | 99.396% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 98.916% |
| FunPep Company Limited | -1.79 Billion JPY | 97.168% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 97.623% |
| Stella Pharma Corporation | -1.11 Billion JPY | 95.463% |
| TMS Co., Ltd. | -3.44 Billion JPY | 98.527% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 99.086% |
| Cuorips Inc. | -5.56 Billion JPY | 99.087% |
| K Pharma,Inc. | -3.26 Billion JPY | 98.445% |
| Takara Bio Inc. | -32.2 Billion JPY | 99.842% |
| ReproCELL Incorporated | -2.93 Billion JPY | 98.272% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 92.317% |
| StemCell Institute Inc. | -2.83 Billion JPY | 98.21% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 97.542% |
| CellSeed Inc. | -2.01 Billion JPY | 97.476% |